Semax Research Guide
Cognitive research peptide
Semax is a synthetic heptapeptide originally developed in the Soviet Union as a stable analogue of the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Across decades of Russian and increasingly international research, it has shown nootropic, neuroprotective, and BDNF-modulating effects in models of stroke, cognitive decline, and stress.
Contents
|
Heptapeptide ACTH 4-10 analogue |
BDNF upregulation Primary mechanism |
Intranasal Common route |
What is Semax?
Semax is a synthetic seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, originally derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH) with stabilizing modifications added at the C-terminus. The terminal Pro-Gly-Pro extension dramatically extends plasma half-life compared to the native ACTH fragment.
Developed at the Russian Academy of Sciences Institute of Molecular Genetics in the 1980s, Semax has been studied extensively in Russian research literature for nootropic and neuroprotective applications. It is approved in Russia for clinical use in stroke recovery and cognitive disorders, with three decades of human safety data accumulated.
Aeternum Labs supplies Semax as a lyophilized powder verified to 99%+ purity by HPLC with mass spectrometry sequence confirmation. Each batch ships with a publicly published Certificate of Analysis tied to the lot number.
Mechanism of action
The dominant mechanism in published Semax research is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and prefrontal cortex. This neurotrophin elevation is hypothesized to underlie the cognitive enhancement and neuroprotective effects observed across multiple animal and human studies.
Secondary mechanisms include modulation of monoamine neurotransmitter systems, particularly dopamine and serotonin. Semax administration produces measurable changes in extracellular dopamine concentrations in striatal and cortical regions in animal microdialysis studies.
Anti-stress effects are mediated through modulation of the hypothalamic-pituitary-adrenal axis, with Semax reducing cortisol and stress-hormone responses in challenge models. This is consistent with its origin as an ACTH-derived peptide that has lost most of the original hormonal activity but retained CNS modulation.
Research history
Semax was developed in the 1980s at the Russian Academy of Sciences Institute of Molecular Genetics as part of a program to identify stable, brain-active analogues of ACTH fragments. The Pro-Gly-Pro C-terminal extension was the key innovation that produced a peptide stable enough for practical research and clinical use.
Russian regulatory approval for Semax in stroke recovery came in the early 1990s. Subsequent approval covered additional cognitive indications. Over the past three decades, more than fifty published clinical and preclinical studies in Russian and English literature have characterized the compound’s nootropic, neuroprotective, and stress-modulating effects.
International research interest has grown over the past decade as the body of Russian-language research becomes more accessible and as the BDNF-upregulation mechanism becomes more relevant to global cognitive aging and depression research.
Half-life and pharmacokinetics
Intranasal administration is the most-studied route in Semax research, with the peptide reaching cerebrospinal fluid within minutes of nasal administration. The intranasal route bypasses first-pass metabolism and may provide direct CNS exposure through olfactory nerve uptake pathways.
Subcutaneous and intramuscular routes are also documented in research, with similar pharmacological effects but slower onset. Plasma half-life is short (minutes), but tissue half-life of effects on BDNF expression extends for days following administration.
Typical research doses
Russian clinical research uses intranasal doses of approximately 600 to 1500 microgram per administration, with frequencies from once to three times daily. Stroke recovery research uses higher doses in the upper end of this range during the acute recovery period.
Cognitive enhancement research in healthy subjects uses lower doses (300-900 microgram intranasally) with daily administration. The dose-response curve for cognitive endpoints appears to plateau in the moderate range, with diminishing returns at the highest tested doses.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
Common stack pairings
Semax + Selank (cognitive + anxiolytic research)
Selank is another Russian-developed peptide with anxiolytic effects that complement Semax’s nootropic profile. Combined research uses both for stress + cognition endpoints simultaneously.
Semax + NAD+ (cognitive aging research)
NAD+ supports mitochondrial function in CNS tissue while Semax upregulates BDNF. The combination addresses both cellular energy and neurotrophic support, relevant in cognitive aging research models.
How it compares
Compared to other ACTH fragment derivatives: Semax is the most-studied stabilized form, with the longest research history and the largest accumulated safety database. Other ACTH fragment derivatives have less established research profiles.
Compared to non-peptide nootropics: Semax acts through neurotrophin upregulation, while compounds like racetams or cholinergics work through different mechanisms (membrane modulation, cholinergic enhancement). Different research questions favor different mechanism classes.
From the Aeternum library
Semax
- 99%+ purity verified by HPLC
- Mass spec sequence confirmation (MEHFPGP)
- LAL endotoxin screening
- Full Certificate of Analysis published
- Lyophilized powder
Frequently asked questions
Where did Semax come from?
Semax was developed in the 1980s at the Russian Academy of Sciences Institute of Molecular Genetics. It is a stabilized analogue of the N-terminal fragment of ACTH (adrenocorticotropic hormone), with C-terminal modifications that extend its plasma half-life and CNS activity.
How is Semax typically administered in research?
Intranasal administration is the most-studied route, with the peptide reaching cerebrospinal fluid within minutes. Subcutaneous and intramuscular routes are also documented but produce slower onset.
What is BDNF and why does Semax upregulate it?
BDNF (brain-derived neurotrophic factor) is a key neurotrophin that supports neuron survival, synaptic plasticity, and learning. Semax upregulates BDNF expression in the hippocampus and prefrontal cortex, which is hypothesized to underlie its observed cognitive enhancement effects in animal and human research.
What dose ranges are used in research?
Russian clinical research uses intranasal doses of 600-1500 microgram per administration in stroke recovery contexts. Cognitive enhancement research in healthy subjects typically uses 300-900 microgram daily.
Is Semax approved for medical use anywhere?
Semax is approved in Russia for clinical use in stroke recovery and cognitive disorders. It is not approved by the FDA in the United States, where it remains a research chemical for in vitro and laboratory use only.
References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. View source
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. (2005). [The efficacy of semax in the treatment of acute stroke]. View source
- Inozemtseva LS, Karpenko EA, Dolotov OV, et al. (2008). Intranasal administration of the peptide Semax affects expression of BDNF in rat hippocampus. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Related research
Category
Best peptides for cognitive research →
Pair with
NAD+ research guide →
Pair with
BPC-157 research guide →
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.